New drug combo aims to shrink liver tumors in kidney cancer patients

NCT ID NCT07256223

Not yet recruiting Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tests a combination of two drugs, envafolimab and lenvatinib, as a first treatment for people with clear cell kidney cancer that has spread to the liver. The study will enroll 30 participants and measure how well the drugs shrink liver tumors. It is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: envafolimab and lenvatinib
What this could lead to: If successful, this combination could offer a new first-line treatment option for kidney cancer patients whose cancer has spread to the liver.
What could go wrong: This is a small, early-phase trial with only 30 participants and no comparison group. The combination may not work better than existing treatments and could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CANCER (CCRCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma nonpapillary renal cell carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLEAR CELL RENAL CELL CANCER (CCRCC) LIVER METASTASIS

More trials for these conditions

Other studies related to the condition(s) this trial covers.